Vaxart, Inc. (VXRT) — SEC Filings
Vaxart, Inc. (VXRT) — 50 SEC filings. Latest: 8-K (May 7, 2026). Includes 34 8-K, 8 DEFA14A, 6 10-Q.
View Vaxart, Inc. on SEC EDGAR
Overview
Vaxart, Inc. (VXRT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Vaxart, Inc. (VXRT) reported a significant increase in revenue from government contracts for the nine months ended September 30, 2025, reaching $131.44 million, a substantial rise from $12.85 million in the same period of 2024. Total revenue for the nine months ended September 30, 2025, was $133.02
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 5 bearish, 42 neutral, 3 mixed. The dominant filing sentiment for Vaxart, Inc. is neutral.
Filing Type Overview
Vaxart, Inc. (VXRT) has filed 34 8-K, 6 10-Q, 8 DEFA14A, 1 10-K, 1 8-K/A with the SEC between Apr 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of VXRT's 48 recent filings, 7 were flagged as high-risk, 17 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $133.02M |
| Net Income | -$38.72M |
| EPS | N/A |
| Debt-to-Equity | 6.81 |
| Cash Position | $16.88M |
| Operating Margin | N/A |
| Total Assets | $208.99M |
| Total Debt | $182.23M |
Key Executives
- Moncef Slaoui
Industry Context
The biotechnology sector, particularly vaccine development, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on government funding, strategic partnerships, and capital markets to finance their operations. The competitive landscape is intense, with a constant drive for innovation in areas like oral delivery methods and novel vaccine platforms.
Top Tags
corporate-governance (9) · regulatory-filing (8) · disclosure (7) · sec-filing (7) · proxy-statement (7) · biotech (7) · filing (6) · 8-K (6) · financials (5) · material-agreement (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $133.02M | For the nine months ended September 30, 2025, up from $13.52 million in 2024 |
| Revenue from government contracts | $131.44M | For the nine months ended September 30, 2025, a significant increase from $12.85 million in 2024 |
| Net Loss | $38.72M | For the nine months ended September 30, 2025, an improvement from $54.96 million in 2024 |
| Research and development expenses | $156.43M | For the nine months ended September 30, 2025, up from $51.56 million in 2024 |
| Cash and cash equivalents | $16.88M | As of September 30, 2025, down from $25.23 million at December 31, 2024 |
| Up-front license fee | $25.0M | Received from Dynavax Technologies Corporation on November 4, 2025 |
| Common stock purchase | $5.0M | By Dynavax Technologies Corporation on November 4, 2025 |
| Total capital received | $30.0M | From Dynavax Technologies Corporation transactions on November 4, 2025 |
| Cash, cash equivalents and short-term investments | $28.8M | As of September 30, 2025, insufficient to fund operations for 12 months |
| Shares of common stock outstanding | 240,069,844 | As of November 6, 2025 |
| Net loss | $30.58M | Improved from a net loss of $40.88 million for the six months ended June 30, 2024, to $30.58 million for the six months ended June 30, 2025. |
| Workforce reduction | 21% | Percentage of workforce reduced in May and June 2025 to decrease operating costs. |
| Net proceeds from March 2025 ATM | $0.1M | From the sale of 382,700 shares during the six months ended June 30, 2025. |
| Net proceeds from June 2024 Offering | $37.5M | From the sale of 50,000,000 shares at $0.80 per share. |
| Net proceeds from 2024 Securities Purchase Agreement | $9.9M | From the sale of 15,384,615 shares at $0.65 per share. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vaxart, Inc. (VXRT)?
Vaxart, Inc. has 50 recent SEC filings from Apr 2024 to May 2026, including 34 8-K, 8 DEFA14A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VXRT filings?
Across 50 filings, the sentiment breakdown is: 5 bearish, 42 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Vaxart, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vaxart, Inc. (VXRT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vaxart, Inc.?
Key financial highlights from Vaxart, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VXRT?
The investment thesis for VXRT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vaxart, Inc.?
Key executives identified across Vaxart, Inc.'s filings include Moncef Slaoui.
What are the main risk factors for Vaxart, Inc. stock?
Of VXRT's 48 assessed filings, 7 were flagged high-risk, 17 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Vaxart, Inc.?
Forward guidance and predictions for Vaxart, Inc. are extracted from SEC filings as they are enriched.